Mentari Therapeutics, Inc. Common Stock (MTRI)

• Market cap: $1.07B
• 1 day: 17.55%
• 5 days: 23.99%
• 1 month: 14.69%
• 3 months: 14.69%
• 6 months: 14.69%
• Year to date: 14.69%
• 1 year: 14.69%
• 5 years: 14.69%
• 10 years: 14.69%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Mentari Therapeutics Inc is a biotechnology company engaged in the development of therapies for the prevention of migraine. Its product pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. The company's research and development activities focus on therapeutic candidates targeting PACAP and CGRP-related mechanisms for migraine prevention.